Your search results will appear here.
Light Mode
Dark Mode
Sign Up
Sign In
Vigil Neuroscience, Inc. logo

Vigil Neuroscience, Inc. (VIGL)

Market Closed
26 Jun, 20:00
NASDAQ (NGS) NASDAQ (NGS)
NASDAQ (NGS) NASDAQ (NGS) Primary
$
7. 95
0
0%
$
369.64M Market Cap
- P/E Ratio
0% Div Yield
395,700 Volume
-2.17 Eps
$ 7.95
Previous Close
Day Range
7.94 7.96
Year Range
1.31 7.96
Want to track VIGL and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
Get Started For Free

Summary

VIGL closed yesterday higher at $7.95, an increase of 0% from Wednesday's close, completing a monthly increase of 0.76% or $0.06. Over the past 12 months, VIGL stock gained 367.65%.
VIGL is not paying dividends to its shareholders.
The last earnings report, released on May 07, 2025, exceeded the consensus estimates by 0.06%. On average, the company has surpassed earnings expectations by 0.01%, based on the last three reports.
The stock of the company had never split.
The company's stock is traded on 1 different exchanges and in various currencies, with the primary listing on NASDAQ (NGS) (USD).

VIGL Chart

Chart

Chart with 60 data points.
The chart has 1 X axis displaying categories.
The chart has 2 Y axes displaying values, and values.
End of interactive chart.
Wall Street Analysts See a 26.1% Upside in Vigil Neuroscience (VIGL): Can the Stock Really Move This High?

Wall Street Analysts See a 26.1% Upside in Vigil Neuroscience (VIGL): Can the Stock Really Move This High?

The mean of analysts' price targets for Vigil Neuroscience (VIGL) points to a 26.1% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Zacks | 2 days ago
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates HURA and VIGL on Behalf of Shareholders

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates HURA and VIGL on Behalf of Shareholders

NEW YORK , June 9, 2025 /PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: TuHURA Biosciences, Inc. (NASDAQ: HURA)'s  merger with Kineta, Inc. If you are a TuHURA shareholder, click here to learn more about your legal rights and options . Vigil Neuroscience, Inc. (NASDAQ: VIGL)'s  sale to Sanofi.

Prnewswire | 2 weeks ago
Wall Street Analysts Think Vigil Neuroscience (VIGL) Could Surge 26.9%: Read This Before Placing a Bet

Wall Street Analysts Think Vigil Neuroscience (VIGL) Could Surge 26.9%: Read This Before Placing a Bet

The average of price targets set by Wall Street analysts indicates a potential upside of 26.9% in Vigil Neuroscience (VIGL). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Zacks | 2 weeks ago

Vigil Neuroscience, Inc. Dividends

VIGL is not paying dividends to its shareholders.

Vigil Neuroscience, Inc. Earnings

7 May 2025 Date
-
Cons. EPS
-
EPS
13 Mar 2025 Date
-
Cons. EPS
-
EPS
7 Nov 2024 Date
-
Cons. EPS
-
EPS
13 Aug 2024 Date
-
Cons. EPS
-
EPS
9 May 2024 Date
-
Cons. EPS
-
EPS
VIGL earnings
VIGL is not paying dividends to its shareholders.
7 May 2025 Date
-
Cons. EPS
-
EPS
13 Mar 2025 Date
-
Cons. EPS
-
EPS
7 Nov 2024 Date
-
Cons. EPS
-
EPS
13 Aug 2024 Date
-
Cons. EPS
-
EPS
9 May 2024 Date
-
Cons. EPS
-
EPS
VIGL earnings

Vigil Neuroscience, Inc. (VIGL) FAQ

What is the stock price today?

The current price is $7.95.

On which exchange is it traded?

Vigil Neuroscience, Inc. is listed on NASDAQ (NGS).

What is its stock symbol?

The ticker symbol is VIGL.

Does it pay dividends? What is the current yield?

Yes, It pays dividends and the current yield is 0%.

What is its market cap?

As of today, the market cap is 369.64M.

Has Vigil Neuroscience, Inc. ever had a stock split?

No, there has never been a stock split.

Vigil Neuroscience, Inc. Profile

Biotechnology Industry
Healthcare Sector
Dr. Ivana Magovcevic-Liebisch J.D., Ph.D. CEO
NASDAQ (NGS) Exchange
92673K108 Cusip
US Country
69 Employees
- Last Dividend
- Last Split
7 Jan 2022 IPO Date
Vigil Neuroscience, Inc., a microglia-focused company, engages in the development of disease-modifying therapeutics for patients, caregivers, and families affected by rare and common neurodegenerative diseases. Its lead product candidate is VGL101, a fully human monoclonal antibody (mAb) that is designed to activate triggering receptor expressed on myeloid cells 2 (TREM2) which is in Phase I for the treatment of adult-onset leukoencephalopathy with axonal spheroids and pigmented glia, as well as for the treatment of cerebral adrenoleukodystrophy and alzheimer's disease. The company also develops a small molecule TREM2 agonist suitable for oral delivery to treat common neurodegenerative diseases associated with microglial dysfunction. Vigil Neuroscience, Inc. was incorporated in 2020 and is headquartered in Cambridge, Massachusetts.

Contact Information

Address: 1 Broadway
Phone: 857 254 4445
Affiliate Program About Report a Bug Terms Privacy Help Contact Us
2025 © Marketlog. All Rights Reserved.
Play store app banner Play store app banner dark App store app banner App store app banner dark
Logo Logo
Sign Up
Sign In